NASDAQ$NKTX
Nkarta Inc · Q1 2024 earnings
Q1 2024 earnings · · Investor relations
Briefing
Reported financial results for the first quarter ended March 31, 2024.
Nkarta reported a cash balance of $450.0 million as of March 31, 2024, bolstered by a recent $240.1 million offering, which is expected to fund operations into late 2027. The company's net loss for the quarter was $29.5 million, or $0.58 per share.
- Dosing of first patient with NKX019 for lupus nephritis using disease-tailored lymphodepletion expected in first half of 2024
- Cash balance of $450.0 million on March 31, 2024, including cash, cash equivalents and investments
- Strong balance sheet, bolstered by recent $240.1 million offering, expected to fund operations into late 2027
- Nkarta expects to announce preliminary data from the NKX019 compressed dosing cohort in mid-2024.
Headline financials
Revenue & EPS history
Nkarta · Revenue · Quarterly
$0
Forward guidance
Nkarta expects its current cash and cash equivalents will be sufficient to fund its current operating plan into late 2027.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports · overlaid with Q1 2024
+0.9%
Avg return
Earnings day
-2.2%
Avg return
5 days after
-0.9%
Avg return
30 days after
63%
15 / 24 earnings
Positive
+16.2%
Q4 2021
Best reaction
-30.3%
Q4 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | +0.9% | -14.8% | — | |
| Q1 2026 | +3.5% | -16.1% | -13.2% | |
| Q3 2025 | +3.1% | -4.6% | -4.6% | |
| Q2 2025 | +12.8% | +19.9% | +0.5% | |
| Q1 2025 | +1.2% | -0.6% | -4.6% | |
| Q4 2024 | +3.2% | -15.4% | +13.3% | |
| Q3 2024 | -4.8% | -9.0% | -23.0% | |
| Q2 2024 | +1.2% | +0.0% | +10.3% | |
| Q1 2024 | -2.3% | +2.3% | +3.1% | |
| Q4 2023 | -30.3% | -22.8% | -43.0% | |
| Q3 2023 | -5.6% | +7.0% | +27.0% | |
| Q2 2023 | -0.5% | -1.0% | -20.5% | |
| Q1 2023 | -4.1% | -4.1% | -0.9% | |
| Q4 2022 | +1.3% | -7.1% | +19.3% | |
| Q3 2022 | -8.4% | -2.1% | -35.5% | |
| Q2 2022 | +8.8% | +11.1% | -8.5% | |
| Q1 2022 | +12.8% | +11.1% | +6.9% | |
| Q4 2021 | +16.2% | +6.2% | -15.2% | |
| Q3 2021 | +7.7% | +7.2% | -15.0% | |
| Q2 2021 | -1.9% | -5.0% | -29.0% | |
| Q4 2020 | +0.0% | -14.4% | -30.3% | |
| Q3 2020 | +2.9% | +14.5% | +122.0% | |
| Q2 2020 | -7.0% | -12.0% | +21.1% | |
| Q1 2021 | +11.3% | — | — | |
| Q4 2019 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro